For laboratory and research use only. Not for human consumption.
peptibase.

The peptibase journal

Peptide science, minus the hype.

Research guides, mechanism breakdowns, and protocol notes. Written for people who actually read the studies.

30 articles

Survodutide Phase 3 Results and the Heart Trial Everyone Is Waiting For
Industry News
Featured

Survodutide Phase 3 Results and the Heart Trial Everyone Is Waiting For

Survodutide, the GLP-1 and glucagon dual agonist, now has two big Phase 3 readouts behind it and a cardiovascular outcomes trial slated for the AHA meeting on November 9. Here is what the data shows, what it does not, and what to watch.

Nov 6, 20266 min read
29 more articles
Peptides Go Mainstream: Telehealth and Pharmacies Chase the Gray Market
Industry News

Peptides Go Mainstream: Telehealth and Pharmacies Chase the Gray Market

After HHS opened a narrow door for six compounded peptides, a telehealth program and a pharmacy network are already pitching gray market customers. Here is what is confirmed, what is marketing, and what the policy does not cover.

Nov 35 min read
CBL-514: The Fat-Cell Killer Being Tested With Tirzepatide
Industry News

CBL-514: The Fat-Cell Killer Being Tested With Tirzepatide

CBL-514 is an injection that makes fat cells self-destruct in one chosen spot. It is in Phase 3 for belly fat, and a new Phase 2 trial pairs it with tirzepatide to tackle stubborn fat and regain after GLP-1s. Here is what the data says so far.

Nov 35 min read
HHS Peptide Policy: BPC-157, TB-500 and 4 More Cleared for Compounding
Industry News

HHS Peptide Policy: BPC-157, TB-500 and 4 More Cleared for Compounding

HHS announced an enforcement discretion policy on October 28 covering BPC-157, TB-500, Semax, Epithalon, KPV and MOTS-c. Here is what it requires, what it does not do, and why FDA staff reportedly objected.

Oct 305 min read
Retatrutide Sleep Apnea Results: What the NEJM Trials Showed
Industry News

Retatrutide Sleep Apnea Results: What the NEJM Trials Showed

Two Phase 3 trials in 691 adults with sleep apnea were published in NEJM on October 20. Retatrutide cut breathing interruptions by up to 34.3 events per hour at 80 weeks. Here is what the data says and what is still unknown.

Oct 275 min read
Peptides for Dogs: What's Real, What's Hype, and What the Sellers Won't Tell You
Research Guides

Peptides for Dogs: What's Real, What's Hype, and What the Sellers Won't Tell You

Peptides for pets are suddenly everywhere, and companies are launching overnight to sell them. Here is the honest breakdown: what BPC-157 might actually do for dogs, what the research really shows (spoiler: it is mostly rats), and the risks nobody promoting this wants to mention.

Jul 248 min read
Topical Peptides for Hair Growth: What's Actually Going Viral (and What the Science Really Says)
Research Guides

Topical Peptides for Hair Growth: What's Actually Going Viral (and What the Science Really Says)

Copper peptides and hair peptides are blowing up, GHK-Cu searches are up over 1,000% this year. Here is an honest, research-first look at GHK-Cu, AHK-Cu, PTD-DBM and topical BPC-157 for hair: what the science actually supports, and what is still hype.

Jul 19 min read
Retatrutide Just Hit Bariatric-Surgery Numbers in Phase 3. Regulators Say Wait Until 2027.
Industry News

Retatrutide Just Hit Bariatric-Surgery Numbers in Phase 3. Regulators Say Wait Until 2027.

Lilly's TRIUMPH-1 reported 28.3% mean body-mass reduction at 80 weeks. That is bariatric-surgery territory from a once-weekly molecule. NDA filing is Q4 2026, approval 2027 at the earliest. What the data says, what it means for the tirzepatide cohort, and the access conversation nobody wants to have.

May 238 min read
Regulators Just Caught Up To What The Research Community Already Knew
Industry News

Regulators Just Caught Up To What The Research Community Already Knew

HHS announced April 15 that 12 peptides are moving from Category 2 back to Category 1 for compounding. Here's what that actually means, why nothing has legally changed yet, and why the regulated pathway won't be the affordable pathway for most people.

Apr 177 min read
A Non-Peptide Just Entered the GLP-1 Race: What Foundayo Means for Peptide Users
Industry News

A Non-Peptide Just Entered the GLP-1 Race: What Foundayo Means for Peptide Users

Regulators just approved an obesity drug that is not a peptide. The peptide GLP-1s still report better numbers. But the landscape just shifted, and the trial data is worth reading side by side.

Apr 510 min read
Chinese Peptide Factories: The Supply Chain Behind Every Vendor (And Why We Cut Out the Middleman)
Safety & Quality

Chinese Peptide Factories: The Supply Chain Behind Every Vendor (And Why We Cut Out the Middleman)

Almost every peptide sold online originates from Chinese synthesis labs. We decided to go direct to the source, so you get factory prices with full quality verification.

Apr 110 min read
TB-500: The Recovery Peptide Athletes Won't Shut Up About
Research Guides

TB-500: The Recovery Peptide Athletes Won't Shut Up About

TB-500 is one of the most popular healing peptides alongside BPC-157. Here is what the research actually shows about its effects, side effects, and why athletes keep talking about it.

Mar 2810 min read
The 2026 Peptide Reclassification: Complete Guide to What Changed
Industry News

The 2026 Peptide Reclassification: Complete Guide to What Changed

On February 27, 2026, 14 peptides were announced to return from Category 2 to Category 1. Here is everything you need to know about what changed, which peptides are affected, and what it means.

Mar 2011 min read
Peptide Sciences Shut Down: Where to Find Trusted Vendors in 2026
Industry News

Peptide Sciences Shut Down: Where to Find Trusted Vendors in 2026

Peptide Sciences closed without warning in March 2026. Here are the verified alternatives our community trusts, with real reviews and exclusive discount codes.

Mar 189 min read
Why Are Peptides Being Restricted? The Regulatory Landscape Explained
Industry News

Why Are Peptides Being Restricted? The Regulatory Landscape Explained

The FDA is going after research peptides — compounds with zero documented deaths — while drugs that kill hundreds of thousands of people a year stay on TV commercials. Here's what's really going on, what the numbers actually say, and why this whole situation is messier than anyone wants to admit. 🤔

Mar 1712 min read
Growth Hormone Peptides and Cancer Risk: What the Research Actually Shows
Peptide Science

Growth Hormone Peptides and Cancer Risk: What the Research Actually Shows

Everyone's heard the claim that GH-releasing peptides like Tesamorelin, CJC-1295, and Ipamorelin cause cancer. Sounds scary — but does the actual clinical evidence back it up? We went through the data so you don't have to.

Mar 1310 min read
Melanotan 2: Way More Than a Tanning Peptide
Peptide Science

Melanotan 2: Way More Than a Tanning Peptide

Most people write off Melanotan 2 as a tanning or libido thing. Honestly? That barely scratches the surface. It taps into melanocortin receptors across nearly every major organ system — and the research on what that means is kind of wild.

Mar 1012 min read
TB-500 and Heart Repair: What the Cardiac Fibrosis Research Actually Shows
Peptide Science

TB-500 and Heart Repair: What the Cardiac Fibrosis Research Actually Shows

TB-500 isn't just for tendon injuries — turns out, the research on heart repair is kind of wild. Published studies show it may actually reverse cardiac fibrosis, cut arrhythmias by 67%, and break the vicious heart-kidney disease cycle. Let's dig into what the science says.

Mar 712 min read
Cardarine (GW501516): What the Research Actually Says About the Cancer Myth
Research Guides

Cardarine (GW501516): What the Research Actually Says About the Cancer Myth

Cardarine isn't a peptide — it's a PPAR-delta agonist with a reputation that's... complicated. Let's dig into what the studies actually show about its metabolic effects, that infamous cancer scare, and why context matters way more than headlines.

Mar 310 min read
BPC-157 As a "Forever Peptide": The Case for Long-Term, Low-Dose Use
Expert Analysis

BPC-157 As a "Forever Peptide": The Case for Long-Term, Low-Dose Use

Most people pop BPC-157 for an injury and call it a day. But here's the thing — emerging research suggests that low-dose, daily BPC-157 might offer systemic benefits that quietly compound over months and years. Let's dig into what the science actually says.

Feb 2712 min read
Retatrutide: Why Researchers Think This Triple Agonist Goes Far Beyond Weight Loss
Peptide Science

Retatrutide: Why Researchers Think This Triple Agonist Goes Far Beyond Weight Loss

Retatrutide hits GLP-1, GIP, and glucagon receptors all at once. And honestly? The weight loss might be the least interesting thing it does.

Feb 2312 min read
Retatrutide: The Triple-Agonist Breaking Every Record in the Trial Data
Trending

Retatrutide: The Triple-Agonist Breaking Every Record in the Trial Data

28.7% mean body-mass reduction reported in Phase 3. The mechanism, the trial record, and why the glucagon arm makes this the most closely watched molecule in development.

Feb 188 min read
The Wolverine Stack: BPC-157 + TB-500 for Accelerated Healing
Research Guides

The Wolverine Stack: BPC-157 + TB-500 for Accelerated Healing

Why the BPC-157 and TB-500 combination dominates the tissue-repair literature. Two different mechanisms, what the animal and human research actually found, and where the evidence runs out.

Feb 1510 min read
BPC-157 and the Regulators: What the 2026 Crackdown Actually Changed
Safety

BPC-157 and the Regulators: What the 2026 Crackdown Actually Changed

Regulators are targeting research peptides. What actually changed in the rules, why it matters, and which pathways remain open for BPC-157.

Feb 119 min read
Reconstitution, Explained: The Step Where Most Lyophilized Peptides Get Wrecked
Education

Reconstitution, Explained: The Step Where Most Lyophilized Peptides Get Wrecked

Bacteriostatic water, concentration math, and the handling mistakes that denature a vial before anyone measures anything. What the published preparation literature actually describes.

Feb 710 min read
Are Peptides Safe? Here's What We Actually Know
Safety

Are Peptides Safe? Here's What We Actually Know

Let's cut through the noise. Some peptides have 40+ years of safety data. Others? We're still figuring it out. Here's the honest breakdown.

Feb 48 min read
How Long Do Peptides Last? Shelf Life Facts Most Vendors Won't Tell You
Education

How Long Do Peptides Last? Shelf Life Facts Most Vendors Won't Tell You

Temperature, light, moisture - which factors actually affect peptide stability? A practical guide to storing your peptides correctly.

Feb 39 min read
The 5 Peptide Combinations With Real Mechanistic Logic Behind Them (2026)
Research Guides

The 5 Peptide Combinations With Real Mechanistic Logic Behind Them (2026)

Which peptide combinations have actual mechanistic reasoning behind them, and which are just two vials sharing a fridge. Five pairings from the research record, the logic for each, and an honest evidence grade.

Jan 3012 min read
Peptides vs SARMs in 2026: Safety, Legality & What Actually Works
Comparisons

Peptides vs SARMs in 2026: Safety, Legality & What Actually Works

Both are research compounds, both are popular in fitness circles, but they're fundamentally different. Here's what you need to know about each.

Jan 2612 min read
Peptides 101: Everything You Need to Know (Without the PhD)
Education

Peptides 101: Everything You Need to Know (Without the PhD)

New to peptides? Same confusing acronyms everywhere? Let's break it down. What they are, how they work, what the research record actually says - explained like you're a smart friend, not a lab rat.

Jan 2318 min read

Request a Topic

Want us to write about a specific peptide or topic? Let us know!

Stay in the loop

Restock alerts, price drops, new guides

Get new articles, research summaries, and peptide science updates delivered to your inbox weekly.

No spam, ever. Unsubscribe anytime.

Popular Topics

BPC-157GLP-1SemaglutideTirzepatideGHK-CuTB-500Healing PeptidesWeight Loss